American

Tributes for Russell Banks, the American novelist who died on Saturday

Comment on this story Comment During America’s renewed mania for book banning, I was disappointed that “Rule of the Bone” didn’t inspire more prigs to start collecting dry sticks. When it came out in 1995, Russell Banks’ graphic, drug-fueled novel about a troubled 14-year-old boy caused a predictable uproar. But now it’s not even on …

Tributes for Russell Banks, the American novelist who died on Saturday Read More »

The Return of Three American Masters — The Best New Crime Thrillers

Crime writers of both sexes — from various countries — often grumble about the fact that America’s crime heavyweights (usually white, male, and late middle-aged) are accorded a gravitas that others struggle to achieve. But I’m afraid this column can’t help the grumblers this week because it begins with three novelists who fit that description …

The Return of Three American Masters — The Best New Crime Thrillers Read More »

Vincerx Pharma Presents Preclinical Data on VIP943 in Models of Acute Myeloid Leukemia at the 2022 American Society of Hematology 64th Annual Meeting.

Vincerx’s proprietary carrier and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significantly improved safety in non-human primates (NHPs) compared to Mylotarg™ (gemtuzumab ozogamicin). VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine …

Vincerx Pharma Presents Preclinical Data on VIP943 in Models of Acute Myeloid Leukemia at the 2022 American Society of Hematology 64th Annual Meeting. Read More »

Kymera Therapeutics Presents Preclinical Data Showing Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in AML xenograft models KT-253 showed combinatorial benefit with the BCL-2 inhibitor venetoclax in a model of venetoclax-resistant AML KT-253 is also active in other hematologic malignancies including DLBCL WATERTOWN, Massachusetts, Dec. 11, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, …

Kymera Therapeutics Presents Preclinical Data Showing Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting Read More »

Coagulant Therapeutics presents data on activated protein C (APC) exosite-specific nanobody library at the American Society of Hematology (ASH) 2022 Annual Meeting.

The oral presentation describes the unique library of APC nanobodies and its potential as a source for novel treatments of diseases including trauma, hemophilia, ischemia and sepsis. SAN FRANCISCO, Dec. 11, 2022 /PRNewswire/ — Coagulant Therapeutics Corporation, a privately held company focused on the design, development and commercialization of therapeutics targeting the coagulation cascade and …

Coagulant Therapeutics presents data on activated protein C (APC) exosite-specific nanobody library at the American Society of Hematology (ASH) 2022 Annual Meeting. Read More »